Background: Fluorophotometry and pneumotonography were performed to investigat e the effect of Latanoprost 0.005%and Placebo on aqueous humor flow and total o utflow facility in human glaucomatous eyes. Methods: In a ...Background: Fluorophotometry and pneumotonography were performed to investigat e the effect of Latanoprost 0.005%and Placebo on aqueous humor flow and total o utflow facility in human glaucomatous eyes. Methods: In a randomised doubleblind clinical study patients with POAG and OHT received either latanoprost 0.005%or placebo once in the evening. Fluorophotometry (Fluorotron Master II, Ocumetrics ) and Pneumatonography (Model 30 Classic Pneumatonometer,Mentor) was performed i n 20 eyes of 10 patients (verum) and 22 eyes of 11 patients (placebo). During a 2 week wash-out period all patients received a systemic antiglaucomatous therap y (Acetazolamide) up to 3 days before baseline measurement. Patients with an IOP higher than 28 mmHg at baseline were excluded. Fluorophotometry, tonography and IOP were measured at baseline after 1 and 2 weeks of treatment. Data was analys ed by the Students paired test. Results: All patients completed the protocol. The IOP significantly decreased (25%) after 1 and 2 weeks of treatment with Lat anoprost (P < 0.01). Fluorophotometry measurements showed no difference in flow over time in both groups. Although tonographic mean C values in both groups did not show any difference over time, the estimated total outflow facility C (Goldmann) increased significantly (P < 0.05) in the verum-treated eyes after 2 weeks. A significant difference of out flow coefficient correlated to normal pressure (PO/C) was found after 2 weeks of treatment with Latanoprost (P < 0.05). Conclusions: In accordance with the lite rature we found a mean 25%decrease in IOP after 2 weeks of treatment with Latan oprost 0.005%. The analysis of flow values in both groups showed no increase or decrease in aqueous humor dynamics as proved in many previous studies. The know n effect of Latanoprost to increase uveoscleral outflow by remodeling extracellu lar matrix and widening intermuscular spaces in the ciliary body may not be dete cted by pneumatonography after 2 weeks of treatment. The significant increase in estimated total outflow facility (Goldmann formula) in latanoprost-treated eye s and the decrease of IOP took place at constant flow rates. The increase in con ventional outflow facility may indicate trabecular meshwork changes, but it cann ot explain the significant decrease in IOP. Furthermore, an additional effect, e .g. uveoscleral outflow, may play the major role as considered in many previous studies.展开更多
文摘Background: Fluorophotometry and pneumotonography were performed to investigat e the effect of Latanoprost 0.005%and Placebo on aqueous humor flow and total o utflow facility in human glaucomatous eyes. Methods: In a randomised doubleblind clinical study patients with POAG and OHT received either latanoprost 0.005%or placebo once in the evening. Fluorophotometry (Fluorotron Master II, Ocumetrics ) and Pneumatonography (Model 30 Classic Pneumatonometer,Mentor) was performed i n 20 eyes of 10 patients (verum) and 22 eyes of 11 patients (placebo). During a 2 week wash-out period all patients received a systemic antiglaucomatous therap y (Acetazolamide) up to 3 days before baseline measurement. Patients with an IOP higher than 28 mmHg at baseline were excluded. Fluorophotometry, tonography and IOP were measured at baseline after 1 and 2 weeks of treatment. Data was analys ed by the Students paired test. Results: All patients completed the protocol. The IOP significantly decreased (25%) after 1 and 2 weeks of treatment with Lat anoprost (P < 0.01). Fluorophotometry measurements showed no difference in flow over time in both groups. Although tonographic mean C values in both groups did not show any difference over time, the estimated total outflow facility C (Goldmann) increased significantly (P < 0.05) in the verum-treated eyes after 2 weeks. A significant difference of out flow coefficient correlated to normal pressure (PO/C) was found after 2 weeks of treatment with Latanoprost (P < 0.05). Conclusions: In accordance with the lite rature we found a mean 25%decrease in IOP after 2 weeks of treatment with Latan oprost 0.005%. The analysis of flow values in both groups showed no increase or decrease in aqueous humor dynamics as proved in many previous studies. The know n effect of Latanoprost to increase uveoscleral outflow by remodeling extracellu lar matrix and widening intermuscular spaces in the ciliary body may not be dete cted by pneumatonography after 2 weeks of treatment. The significant increase in estimated total outflow facility (Goldmann formula) in latanoprost-treated eye s and the decrease of IOP took place at constant flow rates. The increase in con ventional outflow facility may indicate trabecular meshwork changes, but it cann ot explain the significant decrease in IOP. Furthermore, an additional effect, e .g. uveoscleral outflow, may play the major role as considered in many previous studies.
